GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GeneTether Therapeutics Inc. has announced a binding term sheet for a private placement aiming to raise between C$250,000 and C$500,000, and an exclusive license agreement for a promising soft tissue sarcoma drug, STS-201, which also shows potential in other cancers. In conjunction with this agreement, the company will appoint John Rothman, Ph.D., with over 30 years of experience, as its consulting Chief Scientific Officer to advance its strategic medical mission.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.